abraxane

News Story

ABRAXANE(®) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma

11/05/2009

Abraxis BioScience, Inc. announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE(®) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.More »

Abrasis, abraxane, pancreatic cancer

Drug May Extend Life When Breast Cancer Spreads

05/27/2009

TUESDAY, May 26 (HealthDay News) -- A new study affirms that the chemotherapy drug Abraxane is more effective, with less troublesome side effects, than the current drug of choice for metastatic breast cancer. When compared with Taxotere, Abraxane extended the time before a recurrence by almost seven months, effectively doubling survival. Both are members of a class of drugs known as taxanes.More »

abraxane, breast cancer, Cancer, taxotere
Syndicate content